Therapy Areas: Central Nervous System
Transine Therapeutics names Jan Thirkettle PhD as CEO
5 July 2021 -

Biotechnology company Transine Therapeutics revealed on Friday the addition of Jan Thirkettle, PhD as its chief executive officer following the recent successful extended seed financing.

Dr Thirkettle's expertise in guiding biotechnology ventures across all stages of development and his scientific knowledge will be crucial in the development of the company's pipeline of novel mRNA-targeted therapeutics for central nervous system and ophthalmology indications.

Most recently, Dr Thirkettle has served as the start-up CEO and chief development officer at Freeline Therapeutics Holdings (NASDAQ: FRLN).

Earlier in his career, Dr Thirkettle has worked for 18 years at GSK in multiple leadership roles in discovery and manufacturing, including overseeing the establishment of its Cell & Gene Therapy platform unit and playing a pivotal role in the commercialisation of Strimvelis, the first ex-vivo gene therapy to receive an EU Marketing Authorisation Application.



Related Headlines